Table 2.
Mortality and transformation to myeloid leukaemia of Down syndrome (ML-DS) in neonates with Down syndrome and transient abnormal myelopoiesis (TAM)*
| No. of patients | Massey [30] | Klusmann [31] | Muramatsu [32] | Gamis [33••] | Total |
|---|---|---|---|---|---|
| 47 | 146 | 70 | 135 | 398 | |
| Early death | 8 (17 %) | 22 (15 %) | 16 (23 %) | 29 (21 %) | 75 (19 %) |
| TAM-associated hepatic failure | 8 (17 %) | 7 (5 %) | 11 (16 %) | 13 (10 %) | 39 (10 %) |
| Other TAM deaths | 0 | 6 (4 %) | 4 (5.7 %) | 1 (0.7 %) | 11 (3 %) |
| Non-TAM deaths | 0 | 9 (6 %) | 1 (1.4 %) | 15 (11 %) | 25 (6 %) |
| ML-DS (of survivors) | 9 (23 %) | 29 (23 %) | 12 (22 %) | 21 (20 %) | 71 (22 %) |